1st Apr 2010 15:30
Director/PDMR Shareholding
April 1, 2010 - Shire plc , the global specialtybiopharmaceutical company (the "Company") announces that it was notified onMarch 31, 2010 that on the same day the following Ordinary Shares ("Shares")and American Depository Shares ("ADSs") in the Company had been allocated underthe Executive Annual Incentive Plan (the "Plan") to the Executive Directors andPersons Discharging Managerial Responsibility ("PDMRs") set out below. TheShares and ADSs were bought on the market on March 31, 2010 at prices of £14.54per Share and US$66.0571 per ADS. The allocations are in respect of performancein 2009.Name of Director Type of Number of Security Shares/ADSs purchased Angus Russell ADSs 7,421 Graham Hetherington Shares 12,569 Name of PDMR Type of Number of Shares/ADSs security purchased Michael Cola ADSs 3,375 Barbara Deptula ADSs 2,463 Anita Graham ADSs 2,085 Sylvie Gregoire ADSs 3,506 Tatjana May Shares 7,515
Under the terms of the Plan, the Shares and ADSs will not normally be released to participants for three years. One ADS is equal to three Shares.
In addition, on March 31, 2010 the Company was notified of the release of Shares and ADSs in the Company on March 30, 2010 in connection with awards made in 2007 under the Plan to persons who were, at the time of the award, Executive Directors and PDMRs.
In accordance with the rules of the Plan, the following Shares/ADSs werereleased:Name of Director Type of Number of Shares/ADSs Number of Shares/ADSs Security released sold to satisfy tax liabilities Matthew Emmens ADSs 11,534 5,049 Angus Russell Shares 18,140 7,574 Name of PDMR Type of Number of Shares/ADSs Number of Shares/ADSs security released sold to satisfy tax liabilities Michael Cola ADSs 2,944 1,132 Barbara Deptula ADSs 2,402 1,019 Anita Graham ADSs 2,072 797 Tatjana May Shares 8,952 3,737
All Directors and PDMRs sold sufficient Shares or ADSs, on March 30, 2010, at prices of £14.60 per Share and $66.0098 per ADS to satisfy tax liabilities as set out above.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony GuthrieDeputy Company Secretary
For further information please contact:
Investor Relations Cl©a Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 781 482 0999 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release
www.shire.com
vendorRelated Shares:
Shire